Bold take: not all regulatory T cells are the same, and in colorectal cancer that difference can determine whether the tumor grows or stalls. New findings reveal why colorectal cancer defies the usual rule that many Treg cells worsen outcomes. In most solid tumors, high Treg numbers dampen the immune response and correlate with poorer survival. But colorectal cancer behaves differently, and this study explains how two Treg subtypes with opposing roles shape the disease course.
Researchers from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) have identified a mechanism that could refine immunotherapy for most colorectal cancer patients—and perhaps other barrier-tissue cancers such as those of the skin and mucosal linings in the mouth, throat, and stomach. The key insight, published December 15 in Immunity, is that the impact of Tregs depends on their subtype rather than their total count.
Two distinct Treg populations exist in colorectal tumors: one subtype produces the cytokine interleukin-10 (IL-10) and the other does not. Rather than uniformly promoting tumor growth, IL-10–positive Tregs help restrain cancer, while IL-10–negative Tregs support tumor progression. This nuance explains why simply having many Tregs isn’t necessarily bad in colorectal cancer and highlights the need for selective targeting.
Co-senior author Alexander Rudensky, PhD, notes that this discovery shifts the focus from Treg quantity to Treg quality. The team’s experiments show that removing IL-10–positive Tregs accelerates tumor growth because it unleashes Th17 cells, which produce IL-17 and can fuel tumor expansion. Conversely, eliminating IL-10–negative Tregs, which suppress potent anti-tumor CD8+ T cells, leads to tumor shrinkage. In human tumor samples, the same pattern emerges: more IL-10–positive Tregs align with longer survival, while more IL-10–negative Tregs align with poorer outcomes.
The findings build on decades of Rudensky’s work showing that Tregs enforce immune tolerance to prevent harmful reactions to our own tissues and benign microbes, while also playing complex roles in cancer. The current study uses an MSK-developed mouse model that mirrors common colorectal cancer mutations and immune landscapes, enabling precise dissection of Treg subtypes.
Targeting CCR8 as a therapeutic lever
A striking mechanistic clue is that the IL-10–negative, tumor-resident Tregs express high levels of CCR8. This aligns with prior MSK research demonstrating CCR8 as a marker of harmful tumor-associated Tregs across multiple cancers. The implication is clear: CCR8-depleting antibodies could selectively remove the detrimental Tregs while sparing the protective IL-10–positive subset, potentially broadening the effectiveness of immunotherapies. Dr. Rudensky emphasizes that this selective depletion strategy is a leading edge in translating Treg biology into clinical practice.
Early clinical momentum and broader relevance
Numerous trials are already exploring CCR8-targeted approaches, both as standalone therapies and in combination with other immunotherapies. The current colorectal cancer study adds a crucial layer of support for this strategy, suggesting it may improve outcomes for most patients and perhaps extend to other barrier-tissue cancers that share a similar Treg dynamic.
Beyond the colon: a wider pattern
Mitra, Leslie, and Rudensky extended their analysis to a large dataset spanning 16 cancer types, discovering analogous IL-10–positive and IL-10–negative Treg divisions in skin cancers and cancers of the oral and gastrointestinal mucosa. The takeaway is that barrier tissues—constantly exposed to microbes and environmental stress—rely on a delicate balance of Treg subtypes to regulate immunity. If these findings hold, selectively targeting the harmful Tregs could become a universal principle for treating cancers in these tissues.
Metastasis presents a different picture
In liver metastases of colorectal cancer, the balance tilts toward IL-10–negative Tregs, outnumbering the beneficial IL-10–positive cells. In this context, eradicating all Tregs shrinks metastatic tumors, underscoring the need for tissue- and context-specific strategies when addressing metastasis.
Implications, caveats, and next steps
The work points to a refined path forward: therapies that preserve IL-10–positive Tregs while depleting IL-10–negative, CCR8-expressing Tregs may yield better control of tumor growth with fewer collateral effects on beneficial immune regulation. Ongoing and planned clinical trials will test whether this selective approach translates into meaningful benefits for patients with colorectal cancer and possibly other cancers that share this Treg architecture.
If you’re curious about how these findings could reshape treatment paradigms, they raise provocative questions: Should immunotherapy be tailored not just to tumor type but to the internecine politics of its immune cells? Could CCR8-targeted therapy become a standard companion to existing immunotherapies, or even a frontline option for MSS/MMRp colorectal cancer that currently resists checkpoint inhibitors? And for metastases, how might we customize strategies to the tissue context to avoid undermining beneficial Treg populations? Share your thoughts and let’s discuss where you stand on selective Treg depletion as a cancer treatment frontier.
